Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells
Zheng Cao(Hubei University of Medicine), Natasha Kyprianou(Icahn School of Medicine at Mount Sinai)
Cited by 26
Related Papers
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
|Cancer Research|2010|350
Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
|International Journal of Biological Sciences|2014|110
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
|The Prostate|2006|87